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Population Pharmacokinetic Analysis of Diurnal and
Seasonal Variations of Plasma Concentrations of Cilostazol
in Healthy Volunteers
Donghwan Lee, MD, PhD,*† Hankil Son, PhD,*† Lay A. Lim, MD, PhD,*†
and Kyungsoo Park, MD, PhD*†
Background: The background of this study was (1) to examine
factors inﬂuencing cilostazol pharmacokinetics by developing a pop-
ulation model incorporating diurnal variation and other covariate
effects and (2) to assess the feasibility of applying the developed
model to determine the optimal dosing times.
Methods: Data obtained from a cilostazol pharmacokinetic study
consisting of 2 clinical trials (a single twice-a-day (BID) dosing trial
in winter and a multiple BID dosing trial in summer) conducted in
healthy Korean subjects were used for model building. A basic
model was built, followed by a diurnal variation model, and then
a ﬁnal model was built incorporating covariates, including a seasonal
difference. The optimal morning and evening dosing times were
determined from simulations.
Results: Diurnal variation in cilostazol pharmacokinetics was
explained by the morning absorption rate constant being faster than
in the evening, yielding values of 0.278 versus 0.234/h in summer,
when 24- and 12-hour circadian rhythms were included in the model.
The seasonal variation was explained by a 26.9% and a 31.8%
decrease in the absorption rate constant and clearance, respectively,
in winter compared with summer. Based on twice-a-day (BID)
dosing, dosing times of 9 AM and 5 PM in summer and 10 AM and 7
PM in winter were expected to produce the smallest peak-to-peak
ﬂuctuations in cilostazol concentration, possibly minimizing
unwanted effects of the drug.
Conclusions: This study demonstrated the intraday and intersea-
sonal time-varying nature of cilostazol pharmacokinetics using
a population modeling approach and developed a strategy for
optimizing dosing times. It is suggested that these methods can be
similarly applied to analyses and controls of other drugs that exhibit
characteristics of time-varying pharmacokinetics.
Key Words: population model, diurnal variation, seasonal variation,
cilostazol pharmacokinetics, optimal dosing time, therapeutic drug
monitoring
(Ther Drug Monit 2014;36:771–780)
INTRODUCTION
Although pharmacokinetics and pharmacodynamics are
generally assumed to be time invariant, some drugs have been
reported to exhibit time-varying pharmacokinetics or phar-
macodynamics, also called chronokinetics or chronodynam-
ics.1–3 Chronokinetics is observed as variations in absorption,
distribution, metabolism, or excretion and chronodynamics as
variations in drug effects or adverse drug reactions. For exam-
ple, propranolol, a lipophilic antihypertensive drug, has been
reported to be circadian-phase dependent, showing a higher
maximum plasma concentration (Cmax) and an earlier time to
maximum plasma concentration (tmax) after the morning dose
than after the evening dose,4 and heparin has been reported to
exhibit higher anticoagulant effects at night than in the
morning.5
We observed diurnal variations similar to propranolol
in a pharmacokinetic study of cilostazol,6 which is also a lipo-
philic drug. The drug has been used in the treatment of inter-
mittent claudication and in the prevention of coronary artery
diseases and stroke.7–11 In our pharmacokinetic study, we
observed that the Cmax values for cilostazol and its metabolite
(OPC-13015) after the morning dose were 3.53% and 5.11%
higher than after the evening dose, respectively, with a shorter
tmax after the morning dose, and their trough concentrations
before the morning dose were 14.1% and 13.9% higher than
before the evening dose, respectively (Fig. 1, upper panels).
The latter ﬁnding is consistent with results published in the
literature12,13 and demonstrates similar characteristics of many
lipophilic drugs, known to have higher Cmax and shorter tmax
in the morning than in the evening, owing to higher gastro-
intestinal perfusion rates and faster gastric emptying times in
the morning.1,14,15 In addition to diurnal variations, our pre-
vious study found a potential seasonal variation in cilostazol
pharmacokinetics, another source of variation in chronophar-
macokinetics.6 The area under the concentration versus time
curve and Cmax observed in winter were higher than in sum-
mer, with relative increases of 21.57% and 21.67% for cilos-
tazol and 25.02% and 20.60% for OPC-13015, respectively
(Fig. 1, lower panels). The differences in day length and
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temperature between the 2 seasons are approximately 5 hours
and 358C (308C in summer versus 258C in winter), respec-
tively, in Korea, and such differences have been conjectured
to affect the pharmacokinetics of cilostazol.
In our previous study, we found headache to be the
most frequently observed adverse drug reaction to cilosta-
zol.6 The headaches occurred near tmax, indicating that the
adverse drug reaction might be related to the high blood
concentration of cilostazol. Safety data obtained from 8 cil-
ostazol phase 3 trials reported that treatment discontinuation
because of headache occurred in 3.7% of patients who
received a commonly used dose of 100 mg cilostazol BID,
which was more than 10-fold compared with the occurrence
rate of 0.3% in placebo-treated patients.16 Selection of
appropriate dosing times may help to reduce the incidence
of high blood concentrations of cilostazol.
In this study, we aimed (1) to examine factors inﬂuenc-
ing cilostazol pharmacokinetics in the Korean population by
developing a population model incorporating diurnal and
seasonal variations and other covariate effects and (2) to assess
the feasibility of applying the developed model to determine
the optimal dosing times.
METHODS
Cilostazol Plasma Concentrations
The pharmacokinetic data analyzed in this work com-
prised the plasma concentration–time proﬁles for the parent
drug (cilostazol) and its metabolite (OPC-13015) from the
immediate-release formulation of cilostazol (Pletal; Otsuka
Pharmaceutical Co, Ltd, Tokyo, Japan), obtained from a pre-
vious pharmacokinetic study conducted in healthy volunteers.6
In that study, 26 subjects received 100 mg of cilostazol orally
twice a day (8 AM and 8 PM) for 1 day (part A, conducted in
winter 2009) and 40 subjects received 100 mg of cilostazol
orally twice a day (7 AM and 7 PM) for 8 consecutive days (part
B, conducted in summer 2009). In part A and on days 1 and 8
of part B, the subjects were administered the morning dose
after an overnight fast of 10 hours. To minimize food effect
on drug absorption, lunch and sport drinks were provided at 4
and 8 hours after the dose, respectively, and the evening dose
was given at 12 hours after the morning dose, followed by
liquid food 4 hours later. On day 2 through day 7 of part B,
subjects were administered the dose after a 4-hour fast, taking
the meal at 1.5 hours after the administration, to minimize food
effect. Blood samples were collected at 0 (predose), 1, 2, 3, 4,
6, 8, 10, 12, 13, 14, 15, 16, 18, 20, 22, 24, 36, 48, and 72 hours
after the dose for part A and for day 1 and 8 of part B, in which
the last 3 samples at 36, 48, and 72 hours were not collected for
day 1 of part B.
Among the 66 subjects who participated in the study,
63 (26 for part A and 37 for part B) completed the study,
and a total of 3712 cilostazol and OPC-13015 plasma
concentrations were included in the analysis. Given that
OPC-13015 (the ﬁrst metabolite) is 3 times more potent
than cilostazol and that OPC-13213 (the second metabo-
lite) is only 0.33 times as potent as cilostazol, OPC-13213
was not included in the analysis.17 Study participants gave
written informed consent, and the study was approved by
the institutional review board of Yonsei University Sever-
ance Hospital (Seoul, Korea). The study was performed in
accordance with the Declaration of Helsinki18 and Korean
Good Clinical Practice.19 Demographic characteristics of the
63 subjects who completed the study can be found in the pre-
vious work.6
FIGURE 1. Mean observed concentrations of cilostazol (left)
and its metabolite (OPC-13015) (right), reflecting diurnal vari-
ation (upper panels; morning dose, dashed line, versus evening
dose, solid line) and seasonal variation (lower panels; part A,
dashed lines, versus day 1 of part B, solid line). In the upper
panels, the concentration curves for the evening dose (solid
line) have been shifted to the left by 12 hours to be super-
imposed on those for the morning dose. In this and subsequent
figures, except for Figures 2 and 5, x axes denote the time after
the morning dose. Part A represents a single BID dosing trial
conducted in winter and part B a multiple BID dosing trial in
summer. See text for details.
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Population Pharmacokinetic Model
Model building for the parent drug (cilostazol) and its
metabolite (OPC-13015) was performed sequentially, under
the assumption that OPC-13015 does not affect the pharma-
cokinetics of cilostazol. After the ﬁnal pharmacokinetic model
for the parent drug was determined, pharmacokinetic model
building for the metabolite was performed using the posterior
Bayes estimates of the model parameters for the parent drug.
For each of the parent drug and its metabolite, the model-
building process was performed in 3 steps. First, a basic
structural model was built; second, a diurnal variation model;
and ﬁnally, a model incorporating seasonal variation and other
important covariates was developed. Inter-occasion variability
was not included in the model because each subject partici-
pated in only one part of the study, either part A or B.
Basic Model for Cilostazol
A compartment model with ﬁrst-order absorption was
used to build a basic structural model, with an exponential error
model for random interindividual variability as deﬁned below:
P ¼ up$exp

hp

;
where P is the individual pharmacokinetic parameter, uP the
ﬁxed-effect parameter, and hP the interindividual random
effect, distributed as a multivariate normal distribution with
mean zero and variance–covariance matrix V.
Model Incorporating Circadian Variability
The time-varying features of Cmax and tmax of cilostazol
between the morning and evening doses were assumed to
originate from the diurnal variation that might exist in the
bioavailability fraction (F), the absorption rate constant (ka),
and/or the elimination rate constant (CL), as these are directly
related to Cmax and tmax.
In modeling the diurnal variation, F was assumed to
have 2 distinct values between the morning and the evening
doses as follows:
FAM ¼ 1;
FPM ¼ uF;PM$exp

hF;PM

=

1þ uF;PM$exp

hF;PM

;
where FAM and FPM represent the bioavailability of the morn-
ing and evening doses, respectively. The idea was to model
the relative bioavailability of the evening dose assuming that
the morning dose was fully available to the system (FAM = 1).
On the other hand, the diurnal variation of ka and CL
was modeled using the circadian rhythm, which was assumed
to be composed of a sum of cosine functions with different
periods, each being formulated as follows:
CRT ¼ AT$COSð2p=Tðt2BTÞÞ;
AT ¼ uAT$exp

hAT

;
BT ¼ uBT$exp

hBT

;
where CRT is the circadian rhythm pertaining to a cosine
function with period T, amplitude AT, and acrophase ØT,
where AT and ØT are log normally distributed around the
ﬁxed-effect values uAT and uBT via interindividual random
errors hAT and hBT distributed with mean zero and variances
v2AT and v
2
BT
, respectively. Various linear combinations of
cosine functions with different periods were tested, and the
selected combination according to the likelihood ratio test
was included in the model as follows:
CRP ¼ CRP;T1 þ CRP;T2 þ.þ CRP;Tm ;
P ¼ uP$expðCRPÞexpðhPÞ;
where CRP is the overall circadian rhythm for the individual
pharmacokinetic parameter P and CRP;Tj , j = 1, ., m, the
circadian rhythms comprising CRP, each with period Tj.
Selection of Covariates
After a visual inspection of the relationship between
individual post hoc parameter estimates, obtained from
the diurnal variation model and covariates, a regression
analysis using a generalized additive model approach
was performed to initially screen the potential covariates
inﬂuencing each parameter. Based on the model structure
of the diurnal variation model selected in the previous
stage, covariate selection was performed using these
potential covariates and stepwise covariate modeling using
the PsN (Perl-speaks-NONMEM) software (version 3.4.2,
http://psn.sourceforge.net).20,21 Likelihood ratio test was
used to select signiﬁcant covariates, with a signiﬁcance
levels of P ,0.05 for forward selection and P ,0.005
for backward elimination. The following covariates were
tested: age (AGE), body mass index (BMI), weight (WT),
and height (HT) for continuous covariates and caffeine
(XAN), smoking (SMK), alcohol (ALC), gender (SEX),
and season of the conducted study (SEA) for dichotomous
covariates, where SEA reﬂects seasonal variation.
Model for OPC-13015
Model building for OPC-13015 was conducted sequen-
tially by ﬁxing the parent drug model parameters at their
estimates obtained at the previous step of covariate model
building for cilostazol. As for cilostazol, model building
proceeded in the order of basic model, diurnal variation
model, and covariate model building.
Software and Model Evaluation
All analyses described in the Methods were performed
using NONMEM (version 7.2; ICON Development Solu-
tions, Ellicott City, MD), and ADVAN5 and 6 and the First-
Order Conditional Estimation method with INTERACTION
between interindividual and residual variability were used.
All the plots were created using R (http://www.r-project.org).
The ﬁnal model was evaluated by the visual predictive check
(VPC) for 1000 simulations performed using the PsN tool
(version 3.4.2).
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Simulation of Optimal Dosing Scenarios
A set of optimal dosing times, T* ¼ ðT*AM; T*PMÞ, to be
applied in multiple dosing, with T*AM and T
*
PM denoting opti-
mal dosing times in the morning and evening, respectively,
was chosen as the one that minimizes the overall relative error
ERR deﬁned as below, where ðT*AM; T*PMÞ was searched over
TAM = (6, 7,., 11 AM, noon) and TPM = (5, 6,., 11 PM), with
a search interval of 1 hour:
ERR ¼ ðERR1 þ 3ERR2Þ=4;
where ERR1 and ERR2 are the relative errors for cilostazol
and OPC-13015, respectively, with the weighted average
being used considering that OPC-13015 is 3 times more
potent than cilostazol, as reported in the literature.22 ERR1
and ERR2 were deﬁned as follows:
ERRi ¼

ERRi;1 þ ERRi;2

2;  for i ¼ 1; 2;
ERRi;j ¼ abs

Cmax i;j2Targeti

Targeti · 100;
where Cmax i,j and ERRi,j denote the population predicted value
of Cmax given a multiple BID dosing for 8 days and the asso-
ciated error for cilostazol (i = 1) or OPC-13015 (i = 2) for the
morning (j = 1) or the evening dose (j = 2). Targeti denotes the
population predicted value corresponding to the smaller of
Cmax i,1 and Cmax i,2 evaluated at the original dosing times of
8 AM and 8 PM. Given that Cmax i,1 . Cmax i,2 for the original
dosing times, targeti was chosen as Cmax i,2, which was 756.3
and 226.9 ng/mL in summer and 1090.2 and 336.1 ng/mL in
winter for cilostazol and OPC-13015, respectively.
For the computation details, ERR was obtained as
follows. First, for each of the original dosing times and an
optimal dosing time candidate, 1000 datasets were simulated
from the original model. Second, for each simulated dataset k
(k = 1,., 1000), ERRijkl, ERR for individual l (l = 1,., 63) of
simulated dataset k for cilostazol (i = 1) or OPC-13015 (i = 2)
for the morning (j = 1) or the evening dose (j = 2), was com-
puted, followed by ERRikl, the mean of ERRijkl over j. Third,
ERRik, the mean of ERRikl over l, was computed. Fourth,
ERRk, the mean of ERRik over i, was obtained as (ERR1k +
3ERR2k)/4 and, ﬁnally, ERR, the mean of ERRk over k.
The signiﬁcance test for the performance difference
between the original and the optimal sampling time approaches,
as measured by ERR, was conducted using a paired t test
between the 2 sets of 1000 ERRk values obtained from the
2 approaches.
RESULTS
Population Pharmacokinetic Model
Basic Model for Cilostazol
The basic model for cilostazol was best described by
a 2-compartment model with ﬁrst-order absorption; Akaike
TABLE 1. Parameter Estimates for the Final Model With Diurnal Variation and Covariates Included
Parameter Model Equation Ɵ (RSE%)
v2 (coefﬁcient
of variation,
CV%) (RSE%) P
Cilostazol
ka (/h) ka ¼ uka ð1þ ukaSEASON$SEASONÞexpðCRka Þexpðhka Þ uka ¼ 0:229 ð11:7%Þ vka% ¼ 32:7% ð13:8%Þ 0.0018
CRka ¼ A24$COSð2p=24ðt2B24ÞÞ þ A12$COSð2p=12ðt2B12ÞÞ ukaSEASON ¼ 20:269 ð28:5%Þ
A24 AMP24 ¼ uAMP24$expðhAMP24 Þ uAMP24 ¼ 0:291 ð18:8%Þ vAMP24% ¼ 78:8% ð16:0%Þ
Ø24 (h) B24 ¼ uB24 uB24 ¼ 7:44 ð4:24%Þ
A12 AMP12 ¼ uAMP12 uAMP12 ¼ 0:404 ð9:05%Þ
Ø12 (h) B24 ¼ uB24 uB24 ¼ 1:38 ð23:1%Þ
CL (L/h) CL = ƟCL (1 + ƟCL_SEASON$SEASON)$exp(hCL) ƟCL = 13.9 (5.21%) vCL % = 28.3% (10.5%)
ƟCL_SEASON = 20.318 (19.2%) 0.0000
V2 (L) V2 ¼ uV2 uV2 ¼ 45:6 ð14:4%Þ
QP (L/h) QP ¼ uQP uQP ¼ 11:2 ð11:1%Þ
V3 (L) V3 ¼ uV$expðhV3 Þ uV3 ¼ 68:1 ð10:2%Þ vV3% ¼ 65:6% ð15:7%Þ
scilostazol (%) scilostazol = 31.9 (4.73%)
OPC-13015
QPM (L/h) QPM ¼ uQPM uQPM ¼ 16:3 ð12:0%Þ
CLM (L/h) CLM ¼ uCLM$expðhCLM Þ uCLM ¼ 47:7 ð13:3%Þ vCLM% ¼ 19:0% ð9:67%Þ
QM (L/h) QM ¼ uQM$expðhQM Þ uQM ¼ 113 ð23:6%Þ vQM% ¼ 68:3% ð14:6%Þ
V5 (L) V5 ¼ uV5$expðhV5 Þ uV5 ¼ 190 ð15:2%Þ vV5% ¼ 26:6% ð18:6%Þ
sOPC-13015 (%) sOPC-13015 = 26.3 (2.21%)
A24 and Ø24 denote the amplitude and acrophase for a 24-hour rhythm of circadian variation and A12 and Ø12 for a 12-hour rhythm, which comprises the overall circadian variation
in the absorption rate constant for cilostazol, CRka . Residual errors are represented in the unit of coefﬁcient of variation, CV%. P values were obtained by the likelihood ratio test
between the models including and excluding a covariate to be tested. P value denotes the relative importance of the covariate.
The other parameters are deﬁned according to ADVAN6: ka, the absorption rate constant from absorption compartment to central compartment for cilostazol; CL, the clearance for cilostazol; V2,
the central volume of distribution for cilostazol; Qp, the intercompartment clearance between central and peripheral compartments for cilostazol; V3, the peripheral volume of distribution for cilostazol;
QPM, the formation clearance from cilostazol to OPC-13015; QM, the intercompartment clearance between central and peripheral compartments for OPC-13015; CLM, the clearance for OPC-13015;
V5, the peripheral volume of distribution for OPC-13015; RSE, the relative standard error (= standard error of parameter estimate/parameter estimate); SEASON, 0 for summer, 1 for winter.
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information criterion values were 19,052 for the 1-compartment
model, 18,837 for the 2-compartment model, and 18,841 for the
3-compartment model. The pharmacokinetic parameter esti-
mates (percentage of relative standard error%) for the selected
2-compartment model were 0.321/h (10.4%), 80.1 L (10.1%),
11.9 L/h (4.40%), 9.6 L/h (7.70%), and 58.3 L (15.2%) for ka,
V2, CL, Q, and V3, respectively. The interindividual variabil-
ities (coefﬁcient of variation, CV%) for these 5 parameters were
21.8%, 26.0%, 34.6%, 27.4%, and 85.1%, respectively.
Covariance components of the interindividual variability of
pharmacokinetic parameters were not signiﬁcant, so the vari-
ance–covariance matrix V was assumed to be diagonal for the
rest of the model-building process. Residual variability was best
explained by a proportional error model (35.6%).
Model Incorporating Circadian Variability
When the diurnal variation of F was included in the basic
model, it was not signiﬁcant as judged by Akaike information
criterion values (18,846 versus 18,844), so was neglected.
The diurnal variation of ka was best described by a sum
of 24- and 12-hour rhythms. The amplitude (in log scale) and
acrophase were 0.291 and 7.44 hours for a 24-hour rhythm
and were 0.404 and 1.38 hours for a 12-hour rhythm, respec-
tively. When these circadian rhythms were included in ka, the
model improved signiﬁcantly (P , 0.005, DOBJ = 2353).
The degrees of shrinkage in the model parameters of the
diurnal variation model were all less than 23%. Interindivid-
ual variability was found signiﬁcant for A24 only. The diurnal
variation of CL was less signiﬁcant than that of ka and was
not included in the model.
Selection of Covariates
The ﬁnal model reported in Table 1 shows that there
exists a signiﬁcant seasonal variation in ka and CL (P ,
0.005), resulting in a 26.9% decrease in the circadian rhythm
of ka and a 31.8% decrease in CL in part A, as compared with
part B. The estimated precision of the model parameters for
cilostazol was within 30% in relative standard error for the
ﬁxed-effect parameters. The estimated interindividual vari-
ability was larger in absorption and distribution phases, reach-
ing up to 78.8% in coefﬁcient of variation of A24, as
compared with that of the elimination phase, which was less
than 30%. QPM was estimated to be 16.3 L/h. The interindi-
vidual variability of CLM was smaller than that of CL.
Model for OPC-13015
As was found for cilostazol, the 2-compartment model
best described OPC-13015 data as judged by Akaike
information criterion values of 13,722 for the 1-
compartment model, 13,148 for the 2-compartment model,
and 13,150 for the 3-compartment model. As the clearance
of the metabolite and its volume of distribution were not
separately identiﬁable, the central volume of distribution of
metabolite (V4) was ﬁxed to be equal to V2. During the
model-building process, without loss of generality, we
assumed that if diurnal variations in metabolite kinetics
were present, it would be caused by the parent drug; thus,
no additional circadian component was included in the
metabolite model (Table 1). No covariate was found signiﬁcant
during the stepwise covariate modeling process. Figure 2 de-
picts the model structure for cilostazol and OPC-13015 ﬁnally
selected in this work.
Model Evaluation
Figure 3A depicts the goodness-of-ﬁt plot for cilostazol
obtained from the basic model, where the distributions of
residuals show ﬂuctuating trends over time. Figure 3B shows
the goodness-of-ﬁt plot for the ﬁnal model incorporating cir-
cadian rhythms and covariate effects, including seasonal var-
iations for cilostazol and OPC-13015, indicating that there is
a good agreement between model predictions and the data
overall, which supports evidence of the presence of a diurnal
variation in cilostazol pharmacokinetics. In Figure 3A, the
goodness-of-ﬁt plot for OPC-13015 for the basic model was
not obtainable as the metabolite model was built sequentially
after the parent model, including diurnal variation and cova-
riates, was determined.
When evaluated by a VPC, more than 90% of observed
concentrations were included within the 90% prediction
intervals. In the case of cilostazol, the percentages of
observed concentrations below the ﬁfth and above the 95th
percentile prediction curves were 1.96% and 5.88% for part
A, 3.02% and 6.36% for day 1 of part B, and 1.47% and
4.71% for day 8 of part B, respectively. For OPC-13015, they
were 0.975% and 1.75% for part A, 3.51% and 2.23% for day
1 of part B, and 0.978% and 2.51% for day 8 of part B. VPC
results are plotted in Figure 4, showing a good overall agree-
ment between the prediction and the data, although for OPC-
FIGURE 2. Pharmacokinetic model structure finally selected
for cilostazol and OPC-13015. The central volume of distri-
bution of metabolite (V4) was fixed to be equal to V2. See
footnotes to Table 1 for symbols.
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13015 in part B one subject’s data were far above the pre-
diction interval.
The inﬂuence of circadian rhythm on ka predicted by
the ﬁnal model is shown in Figure 5, which shows that, in
summer (part B), the predicted value of ka in the morning
varied between 0.205 and 0.351/h with an average of 0.278/h,
which was faster than that in the evening, varying between
0.114 and 0.354/h with an average of 0.234/h. A similar trend
of a higher rate of ka in the morning than in the evening was
predicted in winter (part A).
Simulation of Optimal Dosing Scenarios
The optimal dosing times were determined to be 9 AM
and 5 PM in summer and 10 AM and 7 PM in winter, yielding
ERRs of 3.00% and 0.89%, respectively, whereas the original
dosing times yielded ERRs of 6.49% and 5.06%, respectively
(Table 2), indicating that the optimal dosing schedule performs
signiﬁcantly better than the original dosing schedule (P ,
0.0001) in minimizing the concentration deviation from the
target concentration.
The predicted concentrations for optimal dosing times
superimposed on the predicted concentrations for the original
dosing times are shown in Figure 6, indicating a lower peak
concentration after the morning dose and a smaller peak-to-
peak ﬂuctuation achieved by the optimal dosing time. Specif-
ically, in the case of summer dosing, the predicted population
values of Cmax for cilostazol obtained using optimal dosing
times, as measured by the median value of 1000 simulations,
were 866.9 ng/mL after the morning dose and 708.3 ng/mL
after the evening dose, which were, respectively, 19.35%
higher and 6.34% lower than the target concentration of
756.3 ng/mL, whereas those for OPC-13015 obtained using
optimal dosing times were 228.9 ng/mL after the morning
dose and 227.1 ng/mL after the evening dose, which were,
FIGURE 3. Goodness-of-fit plots for part A (upper panels), day 1 of part B (middle panels), and day 8 of part B (lower panels)
obtained from (A) the basic model for cilostazol and (B) the final model for cilostazol (left) and OPC-13015 (right). The circles are
conditional weighted residuals with eta–epsilon interaction included, and the solid lines are smooth curves.
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respectively, 0.91% higher and 0.11% higher than the target
concentration of 226.9 ng/mL. On the other hand, in the case
of winter dosing, the predicted values of Cmax for cilostazol
obtained using optimal dosing times were 1147.0 ng/mL after
the morning dose and 1083.4 ng/mL after the evening dose,
which were, respectively, 5.21% higher and 0.62% lower than
the target concentration of 1090.2 ng/mL, whereas those for
OPC-13015 were 335.9 ng/mL after the morning dose and
334.8 ng/mL after the evening dose, which were, respec-
tively, 0.05% lower and 0.38% lower than the target concen-
tration of 336.1 ng/mL. Each 90% prediction band for the
optimal and original dosing times consists of 1000 simula-
tions, based on a set of 63 simulated subjects.
DISCUSSION
The diurnal variation of cilostazol has already been
reported in other pharmacokinetic studies. For example, it was
reported that the steady-state concentration–time proﬁles
showed a trend for the trough concentrations of cilostazol
and its metabolites to be higher before the morning dose
than before the evening dose.12,13 However, none of
the previous studies used a modeling approach to analyze
formally the sources of diurnal variation in cilostazol
pharmacokinetics.
In this study, diurnal variations in Cmax and tmax of
cilostazol were explained by the circadian rhythms in ka
only because allowing for diurnal variation in CL or F did
not signiﬁcantly improve the model. From the biological
point of view, this was considered to be acceptable in that
ka can be affected by changes in posture, blood ﬂow, tissue
perfusion, gastric pH, gastric emptying, and gastrointestinal
motility over a 24-hour period.2 The result using the ﬁnal
model shows that the estimates of the pharmacokinetic pa-
rameters of cilostazol changed considerably when diurnal
variation was included in ka, as compared with the basic
FIGURE 4. VPC for the predicted
concentration of cilostazol (left) and
OPC-13015 (right) for part A (upper
panels), day 1 of part B (middle
panels), and day 8 of part B (lower
panels). The gray areas represent the
90% prediction intervals obtained
from 1000 datasets simulated from
the final model where the thick
curve in the middle denotes the
50th percentile.
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model; the central volume of distribution decreased from
80.1 to 45.6 L, CL increased from 11.9 to 13.9 L/h, Q
increased from 9.60 to 11.2 L/h, and V3 increased from
58.3 to 68.1 L (Table 1). This reﬂects the importance of
considering the inﬂuence of diurnal variation on pharmaco-
kinetics, indicating the possibility of inaccurately assessing
pharmacokinetics, thereby inappropriately suggesting the
treatment guideline when the inﬂuence of diurnal variation
was not taken into account. Interestingly, the inﬂuence of
bioavailability on diurnal variation in cilostazol pharmaco-
kinetics was insigniﬁcant.
When modeling the circadian rhythm in ka, we used an
exponential form rather than an additive form. However, given
that the amplitude of circadian rhythm was much smaller than
1.0 as seen in Figure 5, an additive form, if used, would give
approximately the same result, based on the property of Taylor
series expansion that allows for exp(x) to be approximated by
1 + x when x is small as in this case.
Consistent with the observation in Figure 1, season was
found to affect cilostazol pharmacokinetics signiﬁcantly when
incorporated into ka and CL, which are pharmacokinetic pa-
rameters associated with trough and peak plasma concentra-
tion values of a drug. One seasonal trend consistently
observed in this study was that the mean plasma concentra-
tions of cilostazol and OPC-13015 measured in summer were
lower than in winter.
The value of QPM for OPC-13015 was estimated to be
16.3 L/h, much smaller than that of CLM, which was esti-
mated to be 47.7 L/h. This indicates a possibility of “ﬂip-ﬂop”
phenomenon for OPC-13015, which was also observed in the
previous work done using a noncompartment analysis.6 The
consistent result between the current and the cited works
supports the appropriateness of our model.
In the predicted concentration plots for the optimal
dosing times illustrated in Figure 6, an interesting result was
obtained; the predicted concentration curve did not show
a distinct peak after the evening dose such as was seen after
the morning dose. Instead, it shows a curve that is almost ﬂat
over a period between approximately 8 and 12 hours after
the morning dose (or between 4 PM and 8 PM in clock time)
and very slowly increasing thereafter. We conjecture that
this would be because the predicted absorption rate ap-
proaches its minimum near the evening dosing time of 8
PM (Fig. 5), which might play the role of inhibiting the
concentration increase, resulting in almost a ﬂat concentra-
tion curve over this period.
As OPC-13015 is known to have an antiplatelet
aggregation effect 3 times more potent than cilostazol, it
was important to understand its pharmacokinetics and
inﬂuencing factors. We analyzed OPC-13015 data together
with its parent drug data in our model. Among the
pharmacokinetic parameters of OPC-13015 obtained in this
study, V5 was not an actual value but a ratio of k45/k54 with
V4 being ﬁxed to V2.
Although the most commonly observed adverse drug
reaction in cilostazol is headache and severe adverse drug
reactions rarely occur with a common dose, this study was
conducted in an effort to characterize diurnal variations of
a drug using a pharmacometric approach and to illustrate
how to apply the acquired knowledge to design an optimal
dosing time so as to reduce the incidence of adverse drug
reactions and increase patient compliance. In doing so, we
did not consider changing the dose amount, as the intention
was to ﬁnd the optimal dosing time given the ﬁxed amount
of dose and given the practical difﬁculty with changing
the amount of dose per tablet. In this regard, the control
of seasonal variation, which was unavoidable without
dose adjustment, was not considered for optimizing dosing
scenarios.
Because this work was conducted in healthy volunteers
using the drug concentration as the outcome measure, the
signiﬁcance of the results obtained was tested statistically
only, indicating that diurnal and seasonal variations found to
TABLE 2. Comparison of Relative Errors Obtained From the Original and the Optimal Dosing Times
Season Regimen Dosing Time ERR1 (%) ERR2 (%) ERR (%) P*
Summer Original regimen 7 AM, 7 PM 7.96 6.01 6.49 ,0.0001
Optimal regimen 9 AM, 5 PM 10.48 0.51 3.00
Winter Original regimen 8 AM, 8 PM 6.52 4.57 5.06 ,0.0001
Optimal regimen 9 AM, 6 PM 2.92 0.22 0.89
*Paired t test for ERR between the original and the optimal regimens in each season. See text for the mathematical deﬁnition of ERR1, ERR2, and ERR.
ERR1, the relative error for cilostazol; ERR2, the relative error for OPC-13015; ERR, the overall relative error for cilostazol and OPC-13015.
FIGURE 5. Circadian variation in the absorption rate constant
(ka) predicted from the final model. The dashed line denotes
part A and the solid line part B.
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inﬂuence cilostazol pharmacokinetics signiﬁcantly may be
within the daily variability that a clinician would expect from
their patients and not clinically relevant. Nevertheless, we
consider that the concept and methodology developed here
can be applied similarly to other drugs that have character-
istics of chronokinetics.
In this study, the meal was carefully controlled
to minimize food effects, as the bioavailability of cilostazol
is known to be considerably affected by a high-fat meal.6,23
However, to investigate how the food effect relates to the
diurnal and seasonal variations in cilostazol pharmacokinet-
ics, studies that formally incorporate the food effect into the
model might be needed.
CONCLUSIONS
Using a model-based approach, this study demon-
strated that the time-varying nature of cilostazol pharma-
cokinetics is attributed to diurnal variation, explained by
the increased morning absorption rate, and seasonal variation,
explained by the delayed time to the peak absorption rate
and the decreased drug elimination rate in winter, and
developed a strategy for optimizing dosing times. We
suggest that our methods can be applied similarly to
analyses of other drugs that exhibit characteristics of
time-varying pharmacokinetics.
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